



| Catalog No. | HB895026 |
|---|---|
| Species reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Host species | Human |
| Isotype | IgG1-kappa |
| Clone ID | ATROSAB |
| Biological activity | Atrosab (0.1-1000 nM, preincubate with antibody for 1 h, then add the stimulant TNF and co-incubate for 7 hours) inhibits in a dose-dependent manner the TNF-induced apoptosis of Kym-1 cells [1]. Atrosab (0.1-1000 nM, preincubate with antibody for 1 h, then add the stimulant TNF and co-incubate for 7 hours) inhibits release of IL-6 from HeLa cells and IL-8 from HT1080 cells induced by TNF dose-dependently [1]. Atrosab (100 ug/mL,24 h) reduces endothelial cell expression of adhesion molecules and T cell adhesion [3]. . Inhibited IL-6 release from HeLa cells with an IC 50 of 60 nM. Inhibited IL-8 release from HT1080 cells with an IC 50 of 60 nM. Atrosab (i.v., twice weekly, 28 days) has been shown to be effective for inflammatory diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) in both monkeys and human TNF transgenic/human TNFR1 knock-in mice model and in human TNFR1 knock-in mice (hp55K/i) EAE model [2]. Atrosab (20 mg/kg, i.p.) reduces immune cell infiltrates in humanized TNFR1 knock-in mice [3]. |
| Expression system | Mammalian cells |
| Clonality | Monoclonal |
| Target | TNFR-I, Tumor necrosis factor receptor 1, Tumor necrosis factor receptor superfamily member 1A, TBPI, p60, CD120a, TNFRSF1A, Tumor necrosis factor receptor type I, p55, TNF-RI, TNFAR, TNFR1, TNF-R1 |
| Endotoxin level | Please contact the lab for this information. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P19438 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | ATROSAB |
| Background | Tumor necrosis factor receptor superfamily member 1A (CD120a/TNFR1) is a ~50 kDa protein. Receptor for TNFSF2/TNF and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase. |
| References | 1. Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2010 Nov-Dec;2(6):639-47. [HB895026] 2. Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. [HB895026] 3. E. Guenzi, et al. FRI0231 Atrosab, a humanized antibody directed against tnf-receptor 1, hold great promises for the treatment of rheumatoid arthritis. Ann Rheum Dis. 2013 Jun 14; 72(3):A451. [HB895026] 4. Williams SK, et al. Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Sci Rep. 2018 Sep 11;8(1):13628. View More [HB895026] |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

Detects Recombinant Human CD120a/TNFRSF1A Protein, C-His (Cat No.: HB895011) in indirect ELISA.

SDS-PAGE for Research Grade Anti-Human CD120a/TNFRSF1A/TNFR1 (ATROSAB).




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com




+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский